JulieRachelleHoldenMDMPH
Preventive Medicine • Fort Lauderdale, FLSenior Medical Director, Safety Evaluation and Risk Management
Dr. Holden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Remote
Fort Lauderdale, FL 33301
Education & Training
Tulane University School of Public Health and Tropical MedicineResidency, Public Health and General Preventive Medicine, 2011 - 2012
Duke University HospitalResidency, Radiology-Diagnostic, 2009 - 2010
Brookwood Baptist HealthInternship, Transitional Year, 2008 - 2009
Physicians Medical Center CarrawayInternship, Transitional Year, 2008 - 2008
University of Mississippi School of MedicineClass of 2008
Certifications & Licensure
LA State Medical License 2010 - 2025
NC State Medical License 2010 - 2013
American Board of Preventive Medicine Public Health & General Preventive Medicine
Publications & Presentations
PubMed
- 8 citationsA Meta-Analysis of the Efficacy of Behavioral Interventions to Reduce Risky Sexual Behavior and Decrease Sexually Transmitted Infections in Latinas Living in the Unite...Meghan D. Althoff, Cary T. Grayson, Lucy S. Witt, Julie Holden, Daniel B.C. Reid
Health Education & Behavior. 2015-12-01
Journal Articles
- Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.Sunnåker M, Bhattacharya C, Nelander K, Aurell M, Heijer M, Collén A, Han D, Holden J, Trebski M, Garkaviy P, Ericsson H., Clin Drug Investig., 11/4/2024
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.Bhattacharya CS, Pizzato PE, Heijer M, Sunnåker M, Holden J, Trebski M, Nelander K, Ali H, Genov DK, Aurell M, Collén A, Ericsson H., Br J Clin Pharmacol., 8/12/2024
- Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capac...Lund LH, Lam CSP, Pizzato PE, Gabrielsen A, Michaëlsson E, Nelander K, Ericsson H, Holden J, Folkvaljon F, Mattsson A, Collén A, Aurell M, Whatling C, Baldus S, Drelic..., Eur J Heart Fail., 7/20/2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
